Share Twitter LinkedIn Facebook Email Rod A. Humerickhouse, M.D., PhD Group Project Leader, Oncology Development, AbbVie Discusses Venetoclax In Treatment Of MM At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read